Press release
Arcturus Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
SAN DIEGO--(BUSINESS WIRE)-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global late-stage clinical messenger RNA
About this update from Arcturus Therapeutics Holdings Inc.
[{"type":"text","content":" SAN DIEGO--(BUSINESS WIRE)--\nArcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that the Company will present at the Annual J.P. Morgan Healthcare Conference in San Francisco, on Wednesday, January 11, 2023, at 9:00 a.m. Pacific Time.\n\nA webcast and replay of the presentation will be available on the “Investor Relations/Events” section of the Company’s website at: https://ir.arcturusrx.com/investor-calendar.\n\nAbout Arcturus Therapeutics\n\nFounded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a global late-stage clinical mRNA medicines and vaccines company with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR™ mRNA Technology (samRNA) and (iii) mRNA drug substance along with drug product manufacturing expertise. Arcturus’ diverse pipeline of RNA therapeutic and vaccine candidates includes mRNA vaccine programs for SARS-CoV-2 (COVID-19) and Influenza, and other programs to potentially treat ornithine transcarbamylase (OTC) deficiency, and cystic fibrosis, along with partnered programs including glycogen storage disease type III, and hepatitis B virus. Arcturus’ versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics. Arcturus’ technologies are covered by its extensive patent portfolio (patents and patent applications issued in the U.S., Europe, Japan, China and other countries). For more information, visit www.ArcturusRx.com. In addition, please connect with us on Twitter and LinkedIn.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20221219005237/en/\n\nIR and Media Contacts\nArcturus Therapeutics\nNeda Safarzadeh\nVP, Head of IR/PR/Marketing\n(858) 900-2682\[email protected]\n\nKendall Investor Relations\nCarlo Tanzi, Ph.D.\n(617) 914-0008\[email protected]\n\nSource: Arcturus Therapeutics Holdings Inc.","length":4679,"tagName":"div"}]